2025

  1. Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial

  2. Severe obesity, a susceptibility factor for developing inflammatory bowel disease: results of a population-based study

  3. higher glycemic index and IBD risk